ES2674526T3 - Métodos y composiciones para el diagnóstico de la enfermedad de Alzheimer - Google Patents
Métodos y composiciones para el diagnóstico de la enfermedad de Alzheimer Download PDFInfo
- Publication number
- ES2674526T3 ES2674526T3 ES14726887.4T ES14726887T ES2674526T3 ES 2674526 T3 ES2674526 T3 ES 2674526T3 ES 14726887 T ES14726887 T ES 14726887T ES 2674526 T3 ES2674526 T3 ES 2674526T3
- Authority
- ES
- Spain
- Prior art keywords
- alpha
- complement
- afamin
- protein
- apolipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000003745 diagnosis Methods 0.000 title description 9
- 239000000203 mixture Substances 0.000 title description 3
- 239000000090 biomarker Substances 0.000 claims abstract description 64
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims abstract description 52
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 claims abstract description 52
- 102100036774 Afamin Human genes 0.000 claims abstract description 46
- 101710149366 Afamin Proteins 0.000 claims abstract description 46
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims abstract description 31
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims abstract description 31
- 108010028780 Complement C3 Proteins 0.000 claims abstract description 28
- 102000016918 Complement C3 Human genes 0.000 claims abstract description 28
- 108010028773 Complement C5 Proteins 0.000 claims abstract description 18
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims abstract description 14
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims abstract description 14
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 13
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 13
- 108010075016 Ceruloplasmin Proteins 0.000 claims abstract description 13
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 13
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims abstract description 12
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims abstract description 12
- -1 seroalbumin Proteins 0.000 claims abstract description 11
- 102100031506 Complement C5 Human genes 0.000 claims abstract description 10
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 10
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 10
- 102000013271 Hemopexin Human genes 0.000 claims abstract description 10
- 108010026027 Hemopexin Proteins 0.000 claims abstract description 10
- 101000913082 Homo sapiens IgGFc-binding protein Proteins 0.000 claims abstract description 10
- 102100026103 IgGFc-binding protein Human genes 0.000 claims abstract description 10
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims abstract description 8
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims abstract description 7
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims abstract description 7
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims abstract description 7
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims abstract description 7
- 102000016550 Complement Factor H Human genes 0.000 claims abstract description 4
- 108010053085 Complement Factor H Proteins 0.000 claims abstract description 4
- 238000012544 monitoring process Methods 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 101710104910 Alpha-1B-glycoprotein Proteins 0.000 claims description 18
- 102100033326 Alpha-1B-glycoprotein Human genes 0.000 claims description 18
- 238000007477 logistic regression Methods 0.000 claims description 11
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 10
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 10
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims description 10
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 238000003066 decision tree Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 238000007637 random forest analysis Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000013528 artificial neural network Methods 0.000 claims description 3
- 238000012706 support-vector machine Methods 0.000 claims description 3
- 101710100096 Hornerin Proteins 0.000 claims 2
- 102100028627 Hornerin Human genes 0.000 claims 2
- 102100030013 Endoribonuclease Human genes 0.000 claims 1
- 101710199605 Endoribonuclease Proteins 0.000 claims 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 36
- 239000000523 sample Substances 0.000 description 36
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 20
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000000018 DNA microarray Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 101710145248 Glutathione S-transferase omega-1 Proteins 0.000 description 7
- 102100023541 Glutathione S-transferase omega-1 Human genes 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 102100030386 Granzyme A Human genes 0.000 description 6
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 108010078015 Complement C3b Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100393860 Caenorhabditis elegans gsto-1 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101000906386 Homo sapiens Glutathione S-transferase omega-1 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- JFUIHGAGFMFNRD-UHFFFAOYSA-N fica Chemical compound FC1=CC=C2NC(C(=O)NCCS)=CC2=C1 JFUIHGAGFMFNRD-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000009486 mnemonic function Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Data Mining & Analysis (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Epidemiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Biology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1303936.7A GB2511525A (en) | 2013-03-05 | 2013-03-05 | Methods and Compositions for the Diagnosis of Alzheimer's Disease |
| GB201303936 | 2013-03-05 | ||
| PCT/EP2014/054185 WO2014135546A1 (en) | 2013-03-05 | 2014-03-04 | Methods and compositions for the diagnosis of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2674526T3 true ES2674526T3 (es) | 2018-07-02 |
Family
ID=48142456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14726887.4T Active ES2674526T3 (es) | 2013-03-05 | 2014-03-04 | Métodos y composiciones para el diagnóstico de la enfermedad de Alzheimer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160097780A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2965090B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6430413B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN105164536B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2014224727B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2900002C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2674526T3 (cg-RX-API-DMAC10.html) |
| GB (1) | GB2511525A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014135546A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) * | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| JP6702836B2 (ja) * | 2016-09-28 | 2020-06-03 | ハルメク・ベンチャーズ株式会社 | 認知症判定得点算出装置及びそのプログラム |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| CN118866316A (zh) * | 2017-10-31 | 2024-10-29 | 通用电气健康护理有限公司 | 用于诊断认知疾病病理和/或结果的医疗系统 |
| JP6950952B2 (ja) * | 2017-12-20 | 2021-10-13 | 国立大学法人三重大学 | 脳アミロイド血管症の末梢血バイオマーカー |
| CN108681748A (zh) * | 2018-05-18 | 2018-10-19 | 宝枫生物科技（北京）有限公司 | 判别轻度认知障碍的模型选择处理方法及装置 |
| JP7437376B2 (ja) * | 2018-07-19 | 2024-02-22 | ジェネンテック，インコーポレーテッド | マーカー分子に基づいて、アミロイド陽性認知症を罹患していると、または発症するリスクがあると個体を同定する方法、および関連する使用 |
| CN110464833A (zh) * | 2019-09-04 | 2019-11-19 | 北京豪思生物科技有限公司 | 铜蓝蛋白的应用 |
| WO2021071219A1 (ko) * | 2019-10-07 | 2021-04-15 | 조한나 | 퇴행성 신경질환의 진단용 바이오마커 |
| JP7109499B2 (ja) * | 2020-05-07 | 2022-07-29 | 一般社団法人脳と心の健康科学研究所 | 認知症判定得点算出装置及びそのプログラム |
| CN115066615A (zh) * | 2020-12-28 | 2022-09-16 | 株式会社Mcbi | 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置 |
| ES2924776A1 (es) * | 2021-03-25 | 2022-10-10 | Univ Castilla La Mancha | Metodos para el diagnostico y pronostico de la enfermedad de alzheimer |
| CN112858697B (zh) * | 2021-03-29 | 2024-03-01 | 鲁东大学 | ALG-2-interacting protein X在制备分子标志物中的应用 |
| CN114634970A (zh) * | 2022-03-29 | 2022-06-17 | 南通惠皓医疗科技有限公司 | 遗传性阿尔兹海默症致病基因panel检测方法 |
| CN116990395A (zh) * | 2022-04-26 | 2023-11-03 | 中国科学院深圳先进技术研究院 | 一种基于粪便的阿尔兹海默症生物标志物及其应用 |
| WO2024004944A1 (ja) * | 2022-06-28 | 2024-01-04 | 株式会社Mcbi | 判定支援情報生成方法、判定支援情報生成システム、及び情報処理装置 |
| CN116063447B (zh) * | 2022-09-13 | 2023-11-03 | 北京湃德智健科技有限公司 | 用于检测adap自身抗体的抗原多肽及其应用 |
| US20240138749A1 (en) * | 2022-10-31 | 2024-05-02 | Movalytix, Inc. | Method for screening of movement disorders |
| CN119495355B (zh) * | 2024-10-31 | 2026-04-24 | 山东大学 | 一种阿尔兹海默症诊断标志物的筛选方法和系统 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH067191A (ja) * | 1991-09-26 | 1994-01-18 | Konica Corp | モノクローナル抗体、それを産生するハイブリド−マ、その対応抗原及びそれを用いた測定方法 |
| US5652352A (en) * | 1994-03-31 | 1997-07-29 | Amgen Inc. | Afamin: a human serum albumin-like gene |
| AT411014B (de) * | 2001-04-30 | 2003-09-25 | Vitateq Biotechnology Gmbh | Präparationen von vitamin e in kombination mit afamin |
| DE60225821T2 (de) * | 2001-10-04 | 2009-04-30 | Immuno-Biological Laboratories Co., Ltd., Takasaki | Reagens zum Nachweis eines Risikofaktors der Alzheimer-Krankheit, Nachweiskit dafür und Verfahren zum Nachweis eines Risikofaktors der Alzheimer-Krankheit unter ihrer Verwendung |
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| WO2006108051A2 (en) * | 2005-04-05 | 2006-10-12 | Neurodx, Llc | Compositions and methods relating to alzheimer's disease |
| GB0512401D0 (en) * | 2005-06-17 | 2005-07-27 | Randox Lab Ltd | Method |
| US7575876B2 (en) * | 2005-10-27 | 2009-08-18 | The University Of Washington | Biomarkers for neurodegenerative disorders |
| AT505727B1 (de) * | 2007-09-04 | 2009-06-15 | Univ Innsbruck | Verfahren zur diagnose des metabolischen syndroms |
| GB0921447D0 (en) * | 2009-12-04 | 2010-01-20 | Randox Lab Ltd | Assay |
| CA2799351A1 (en) * | 2010-05-14 | 2011-11-17 | Rules-Based Medicine, Inc. | Methods and devices for diagnosing alzheimers disease |
| JP6198752B2 (ja) * | 2012-01-20 | 2017-09-20 | アデレード リサーチ アンド イノベイション ピーティーワイ エルティーディーＡｄｅｌａｉｄｅ Ｒｅｓｅａｒｃｈ ＆ Ｉｎｎｏｖａｔｉｏｎ Ｐｔｙ Ｌｔｄ | 胃癌のバイオマーカー及びその使用 |
| ITMI20120865A1 (it) * | 2012-05-18 | 2013-11-19 | Antonio Bertolotto | Biomarcatori per patologie del sistema nervoso centrale |
-
2013
- 2013-03-05 GB GB1303936.7A patent/GB2511525A/en not_active Withdrawn
-
2014
- 2014-03-04 EP EP14726887.4A patent/EP2965090B1/en active Active
- 2014-03-04 ES ES14726887.4T patent/ES2674526T3/es active Active
- 2014-03-04 AU AU2014224727A patent/AU2014224727B2/en active Active
- 2014-03-04 CN CN201480008554.4A patent/CN105164536B/zh active Active
- 2014-03-04 WO PCT/EP2014/054185 patent/WO2014135546A1/en not_active Ceased
- 2014-03-04 JP JP2015560663A patent/JP6430413B2/ja active Active
- 2014-03-04 US US14/777,718 patent/US20160097780A1/en not_active Abandoned
- 2014-03-04 CA CA2900002A patent/CA2900002C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2965090B1 (en) | 2018-04-25 |
| JP2016511406A (ja) | 2016-04-14 |
| CN105164536A (zh) | 2015-12-16 |
| AU2014224727B2 (en) | 2020-09-03 |
| EP2965090A1 (en) | 2016-01-13 |
| GB201303936D0 (en) | 2013-04-17 |
| AU2014224727A1 (en) | 2015-08-13 |
| JP6430413B2 (ja) | 2018-11-28 |
| CA2900002C (en) | 2022-01-25 |
| US20160097780A1 (en) | 2016-04-07 |
| GB2511525A (en) | 2014-09-10 |
| CA2900002A1 (en) | 2014-09-12 |
| WO2014135546A1 (en) | 2014-09-12 |
| CN105164536B (zh) | 2018-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014224727B2 (en) | Methods and compositions for the diagnosis of Alzheimer's disease | |
| Hu et al. | Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays | |
| RU2675370C2 (ru) | Способ выявления присутствия или отсутствия агрессивного рака предстательной железы | |
| Chahine et al. | Blood-based biomarkers for Parkinson's disease | |
| Shaw et al. | Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | |
| ES2612197T3 (es) | Marcadores en la orina para la detección del cáncer de vejiga | |
| ES2694409T3 (es) | Método de pronóstico para individuos con cáncer de próstata | |
| JP5878875B2 (ja) | アルツハイマー病の診断法 | |
| ES2706534T3 (es) | Método para ayudar al diagnóstico diferencial del accidente cerebrovascular | |
| Li et al. | UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis | |
| HK1248316A1 (en) | Methods of assessing colorectal health of an individual | |
| BRPI0709374A2 (pt) | técnica de obtenção de impressão digital de apolipoproteìna e métodos relacionados á mesma | |
| TWI868698B (zh) | 用於快速診斷川崎病的分子生物標誌物和分析方法 | |
| ES2361808B1 (es) | Método de obtención de datos útiles para el diagnóstico o el pronóstico del c�?ncer colorrectal. | |
| US10078089B2 (en) | Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome | |
| ES2975228T3 (es) | Derivados de GFAP para el diagnóstico de accidente cerebrovascular | |
| Everest et al. | Prospective outcome analysis of multiple sclerosis cases reveals candidate prognostic cerebrospinal fluid markers | |
| AU2021203920A1 (en) | Biomarkers for detection of breast cancer | |
| CN113699235A (zh) | 免疫原性细胞死亡相关基因在头颈鳞癌生存预后及放疗应答性中的应用 | |
| KR102136747B1 (ko) | 장형 위암의 예후 진단 마커 | |
| Seyhan | Biomarkers in drug discovery and development | |
| AU2018100578A4 (en) | Method for detection & diagnosis of oral cancer in a sample | |
| CN117385034A (zh) | 标志物组合在制备预测肝癌患者预后治疗疗效产品中的应用 | |
| KR20250097696A (ko) | Reg3a를 포함하는 ctnnb1 돌연변이 간암 진단용 바이오마커 조성물 | |
| ES2686736T3 (es) | Combinaciones de biomarcadores para su uso en la detección del cáncer de páncreas |